AstraZeneca PLC (AZN)vsBiomotion Sciences Ordinary Shares (SLXN)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
SLXN
Biomotion Sciences Ordinary Shares
$0.36
-15.43%
HEALTHCARE · Cap: $1.96M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
SLXN
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for SLXN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
No standout strengths identified
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : SLXN
SLXN has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : SLXN
The primary concerns for SLXN are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 32.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while SLXN is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.20 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 16/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Biomotion Sciences Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Biomotion Sciences (SLXN) is a forward-thinking biotechnology firm specializing in regenerative medicine, focused on developing innovative therapies to address severe medical conditions with substantial unmet needs. The company boasts a promising pipeline of product candidates designed to enhance patient care and outcomes significantly. With a commitment to research and development, along with strategic collaborations, Biomotion Sciences is poised to make transformative contributions to the biotechnology landscape, making it an attractive investment prospect for institutional investors interested in advanced therapeutic solutions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?